Across TCGA pan-cancer cohorts, LYPD2 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of LYPD2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where LYPD2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types LYPD2 is over-expressed in tumor, although a few such as HNSC and LUAD show the opposite, repressed pattern.

HNSC, PDAC, and LUAD are the cancer types where LYPD2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LYPD2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	−1.241	<.001	11	view →
PDAC	All	All	+1.240	.039	1	view →
LUAD	All	All	−1.037	.010	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: LYPD2 RNA expression & survival · all LYPD2 data types